Drugs / BAY86-6150
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01921855 | Jan → Dec 2009 | hemophilia A, hemophilia B | Bayer | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01625390 | Jun 2012 → Mar 2014 | hemophilia A, hemophilia B | Bayer | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAY 86-6150 | “BAY 86-6150 is a new human recombinant factor VIIa variant developed for high procoagulant activity and longer action in people with hemophilia with inhibitors.” PMID 22353395 ↗ May 2012 |
| Known as | BAY Factor VII | “BAY Factor VII (BAY86-6150), 6.5 µg/kg body weight, will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.” NCT01921855 ↗ |
| Modality | Protein / enzyme biologic | “Modified rFVIIa BAY86-6150” NCT01625390 ↗ |
| Route | Intravenous | “will be administered as a slow intravenous (i.v.) administration” NCT01921855 ↗ |